Enterin

About Enterin

We are a clinical stage biopharmaceutical company engaged in the discovery and development of synthetic derivatives of newly discovered endogenous hormones that target misfolded proteins, including alpha-synuclein in Parkinson’s Disease, or PD, amyloid beta and tau in Alzheimer’s Disease, or AD, as well as targeting insulin resistance which is central to the pathology of Type 2 Diabetes, or T2D, and AD. Our vision is to prevent the onset of these neurodegenerative and metabolic disorders, as well as to slow their progression.